PHVS

Pharvaris

Pharvaris develops oral bradykinin B2 receptor antagonists to treat patients with hereditary angioedema and other bradykinin-mediated diseases.

VTYX

This biopharmaceutical company develops oral small-molecule medicines for patients with autoimmune, inflammatory, cardiovascular and neurodegenerative diseases.

APLS

This biopharmaceutical company develops complement-based therapies to treat autoimmune and inflammatory diseases for patients with conditions like paroxysmal nocturnal haemoglobinuria and geographic atrophy.

Pharos IBT

This company develops artificial intelligence platforms for discovering and developing treatments for rare and refractory diseases for the pharmaceutical and biotechnology industries.

Strategic Partners

This company develops drug candidates for serious genetic disorders to serve patients with rare diseases.

Dyax

This biotechnology firm develops pharmaceutical treatments for hereditary angioedema and other plasma-kallikrein-mediated disorders to assist patients with these rare inflammatory conditions.

VectivBio

This company develops biopharmaceutical treatments for severe rare gastrointestinal conditions, including short bowel syndrome, for patients with orphan diseases.

X4 Pharmaceuticals

This biopharmaceutical company develops and commercialises oral therapies for patients with rare immune system disorders, such as WHIM syndrome and chronic neutropenia.